Medpace Holdings, Inc. (MEDP): A Bull Case Theory

We came across a bullish thesis on Medpace Holdings, Inc. (MEDP) on Substack by Compound & Fire. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc. (MEDP)'s share was trading at $305.98 as of May 19^th. MEDP’s trailing and forward P/E were 23.36 and 24.88 respectively according to Yahoo Finance.

Medpace Holdings is a leading global clinical research organization (CRO) founded in 1992, delivering comprehensive clinical trial management services to biotech, pharmaceutical, and medical device sectors, with a strong focus on oncology and cardiology. Operating in 44 countries and employing around 5,900 people, Medpace emphasizes a high-science, disciplined approach that drives quality and efficiency in clinical development.

The company boasts a robust financial profile, with a net debt-to-EBITDA ratio of -1.1x, strong capital efficiency, and operating cash flow exceeding net income by 150%. Its capital-light model, disciplined capital allocation—including a recent $1 billion share buyback program—and strong profitability with gross margins of 67.7% and net margins of 19.2% establish Medpace as a resilient, high-quality compounder in the CRO space. The CRO industry itself is poised for significant growth, expected to reach $71 billion in 2024 and grow at a 7% to 9.6% CAGR over the next decade, driven by rising R&D spending, trial complexity, and outsourcing.

Medpace’s vertically integrated, full-service model caters mainly to small and mid-sized biotech firms, representing 96% of revenue, and is differentiated by proprietary technology like ClinTrak and AI-driven imaging analytics that enhance margins and client retention. Despite near-term headwinds from a declining book-to-bill ratio, competition, potential biotech funding cuts, and operational challenges, Medpace’s $2.85 billion backlog, global presence, and client relationships provide long-term resilience. Valuation appears modestly undervalued, with a reverse DCF implying conservative growth, and base case modeling forecasts 12.2% annual returns. Overall, Medpace offers a compelling investment opportunity combining strong fundamentals, growth potential, and a balanced risk-reward profile as a science-driven healthcare compounder.

Medpace Holdings, Inc. (MEDP) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 42 hedge fund portfolios held MEDP at the end of the fourth quarter which was 41 in the previous quarter. While we acknowledge the risk and potential of MEDP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MEDP but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article was originally published at Insider Monkey.